NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
»24/10/2009 [Industry news]
30% of China\'s Hepatitis B patients can\'t afford long-term treatment

Nearly 30 percent of Hepatitis B patients in China do not stick to long-term medical treatment or take medicine less frequently than they should due to lack of money, according to a survey published here Friday.

 
(Xinhua) -- Nearly 30 percent of Hepatitis B patients in China do not stick to long-term medical treatment or take medicine less frequently than they should due to lack of money, according to a survey published here Friday. These patients skipped medicines at will, switched to cheaper drugs or even stopped treatment due to money concern. Also 42 percent of the respondents do not visit doctors regularly. The survey on Hepatitis B patients treatment, jointly launched by the Chinese Foundation for Hepatitis Prevention and Control and the Chinese Society of Hepatology under the Chinese Medical Association in April, covered some ten thousand Hepatitis B patients in 21 provinces. Also the survey showed nearly 60 percent of respondents are not aware of the necessity of long-term antiviral treatments and 41 percent thought such treatment should be no longer than two years. Zhuang Hui, an epidemiologist and a member of the Chinese Academy of Engineering, said Hepatitis B patients should take antiviral drugs orally for at least two years. Zhuang advised patients to consult doctors to figure out a treatment plan in accordance with both their disease situation and income level in order not to give up treatment halfway. Editor: Yan

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.